Education
About Us
Working with TipRanks
Follow Us
Seres Therapeutics Inc. (MCRB)
:MCRB
MCRB Stock Chart & Stats
$18.52
>-$0.01(-0.25%)
At close: 4:00 PM EST
$18.52
>-$0.01(-0.25%)
Day’s Range― - ―
52-Week Range$6.53 - $24.67
Previous CloseN/A
Volume457.00K
Average Volume (3M)113.93K
Market Cap
$147.86M
Enterprise Value$139.20M
Total Cash (Recent Filing)$45.38M
Total Debt (Recent Filing)$87.43M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Nov 18, 2025EPS Estimate
0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.27
Shares Outstanding8,754,570
10 Day Avg. Volume81,504
30 Day Avg. Volume113,928
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue23.36
Enterprise Value/Gross Profit-46.23
Enterprise Value/Ebitda-1.29
Forecast
1Y Price Target
$22.00Price Target Upside18.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
FDA Approval PotentialMaintain BUY, raising price target to $22 based on positive feedback from the higher probability of FDA approval.
Financial OutlookSeres currently holds ~$45.4M in cash and expects ~$25M Nestle payment in 3Q25, supporting a cash runway into 2Q26.
Strategic PartnershipsFDA provided feedback on Seres' proposed Phase 2 SER-155 study in bloodstream infections, which could aid in partnership discussions.
Bears Say
Leadership ChangesLong-time CEO Eric Shaff would depart the company, with CLO Thomas DesRosier and CFO Marella Thorell appointed as co-CEOs.
Seres Therapeutics News
MCRB FAQ
What was Seres Therapeutics Inc.’s price range in the past 12 months?
Seres Therapeutics Inc. lowest stock price was $6.53 and its highest was $24.66 in the past 12 months.
What is Seres Therapeutics Inc.’s market cap?
Seres Therapeutics Inc.’s market cap is $147.86M.
When is Seres Therapeutics Inc.’s upcoming earnings report date?
Seres Therapeutics Inc.’s upcoming earnings report date is Nov 18, 2025 which is in 18 days.
How were Seres Therapeutics Inc.’s earnings last quarter?
Seres Therapeutics Inc. released its earnings results on Aug 06, 2025. The company reported -$2.27 earnings per share for the quarter, beating the consensus estimate of -$2.49 by $0.22.
Is Seres Therapeutics Inc. overvalued?
According to Wall Street analysts Seres Therapeutics Inc.’s price is currently Undervalued.
Does Seres Therapeutics Inc. pay dividends?
Seres Therapeutics Inc. does not currently pay dividends.
What is Seres Therapeutics Inc.’s EPS estimate?
Seres Therapeutics Inc.’s EPS estimate is 0.46.
How many shares outstanding does Seres Therapeutics Inc. have?
Seres Therapeutics Inc. has 8,754,570 shares outstanding.
What happened to Seres Therapeutics Inc.’s price movement after its last earnings report?
Seres Therapeutics Inc. reported an EPS of -$2.27 in its last earnings report, beating expectations of -$2.49. Following the earnings report the stock price went down -3.501%.
Which hedge fund is a major shareholder of Seres Therapeutics Inc.?
Currently, no hedge funds are holding shares in MCRB
Seres Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$22.00 (18.79% Upside)
$22.00 (18.79% Upside)
Blogger Sentiment
Bullish
MCRB Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 163.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.51%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-55.30%
Trailing 12-Months
Company Description
Seres Therapeutics Inc.
Seres Therapeutics, Inc. (MCRB) is a biotechnology company focused on developing microbiome therapeutics. The company operates in the healthcare sector and is dedicated to creating innovative treatments for diseases by harnessing the therapeutic potential of the human microbiome. Seres Therapeutics' core products include a pipeline of biologically-derived drugs aimed at treating diseases such as Clostridium difficile infection (CDI) and other conditions linked to dysbiosis of the gut microbiota.
MCRB Company Deck
MCRB Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a generally optimistic outlook with significant progress in key areas such as the development of SER-155, financial management improvements, and strategic partnerships. However, the call also highlighted challenges related to the biotech environment and cash runway limitations, indicating a need for securing additional capital.View all MCRB earnings summariesMCRB Stock 12 Month Forecast
Average Price Target
$22.00
▲(18.79% Upside)
Technical Analysis
Jasper Therapeutics
―
Elicio Therapeutics
―
Vor Biopharma
―
Instil Bio
―
Senti Biosciences
―
Ownership Overview
2.45% Insiders
8.40% Mutual Funds
13.70% Other Institutional Investors
71.59% Public Companies and
Individual Investors